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ABSTRACT The outcome ofMycobacterium tuberculosis infection and the immunological response to the bacillus Calmette-
Guerin (BCG) vaccine are highly variable in humans. Deciphering the relative importance of host genetics, environment, and
vaccine preparation for the efficacy of BCG has proven difficult in natural populations. We developed a model system that cap-
tures the breadth of immunological responses observed in outbred individual mice, which can be used to understand the contri-
bution of host genetics to vaccine efficacy. This system employs a panel of highly diverse inbred mouse strains, consisting of the
founders and recombinant progeny of the “Collaborative Cross” project. Unlike natural populations, the structure of this panel
allows the serial evaluation of genetically identical individuals and the quantification of genotype-specific effects of interventions
such as vaccination. When analyzed in the aggregate, our panel resembled natural populations in several important respects: the
animals displayed a broad range of susceptibility toM. tuberculosis, differed in their immunological responses to infection, and
were not durably protected by BCG vaccination. However, when analyzed at the genotype level, we found that these phenotypic
differences were heritable.M. tuberculosis susceptibility varied between lines, from extreme sensitivity to progressiveM. tuber-
culosis clearance. Similarly, only a minority of the genotypes was protected by vaccination. The efficacy of BCGwas genetically
separable from susceptibility toM. tuberculosis, and the lack of efficacy in the aggregate analysis was driven by nonresponsive
lines that mounted a qualitatively distinct response to infection. These observations support an important role for host genetic
diversity in determining BCG efficacy and provide a new resource to rationally develop more broadly efficacious vaccines.
IMPORTANCE Tuberculosis (TB) remains an urgent global health crisis, and the efficacy of the currently used TB vaccine,M. bo-
vis BCG, is highly variable. The design of more broadly efficacious vaccines depends on understanding the factors that limit the
protection imparted by BCG.While these complex factors are difficult to disentangle in natural populations, we used a model
population of mice to understand the role of host genetic composition in BCG efficacy. We found that the ability of BCG to pro-
tect mice with different genotypes was remarkably variable. The efficacy of BCG did not depend on the intrinsic susceptibility of
the animal but, instead, correlated with qualitative differences in the immune responses to the pathogen. These studies suggest
that host genetic polymorphism is a critical determinant of vaccine efficacy and provide a model system to develop interventions
that will be useful in genetically diverse populations.
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The outcome of an encounter with Mycobacterium tuberculosisis highly variable. Most individuals contain the infection and
can remain asymptomatic for a lifetime. Only a fraction of in-
fected individuals develop active disease, and even among these,
the timing, location, and presentation of the pathology is remark-
ably diverse (1). The underlying basis of the variable outcomes of
M. tuberculosis infection is unknown and likely involves a complex
interplay between environmental factors and genetic variation in
both host and pathogen (2). Classic evidence for a role of host
genetics driving disease outcome comes from twin studies show-
ing a higher tuberculosis (TB) concordance rate in monozygotic
than in dizygotic twins (3, 4). More recently, linkage analyses de-
fined rare Mendelian traits that cause extreme susceptibility to
mycobacterial disease in children (5–9), and a variety of case-
control (10, 11), linkage (12), or genome-wide association studies
(13, 14) have implicated more common genetic variants in TB
risk. The identification of these TB-associated polymorphisms
provides valuable insight into the pathogenesis of this disease, as
many of the identified genes function in the establishment of a
protective Th1-biased cell-mediated immune response (15), reg-
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ulate disease-promoting inflammation (16, 17), or alter the
pathogen’s intracellular environment (18). However, these
knownmechanisms explain only a small fraction of the variability
observed in natural populations (2), suggesting an important role
for interactions between these and other disease-modifying poly-
morphisms.
This diversity in TB susceptibility is mirrored in the variable
efficacy of vaccination for this disease. The only TB vaccine that
has been shown to protect humans is an attenuated strain ofMy-
cobacterium bovis, bacillus Calmette-Geurin (BCG). This vaccine
has been administered to more than 3 billion humans since it was
developed in the 1920s. In the subsequent decades, studies in dif-
ferent geographic regions and ethnic populations have produced
widely variable estimates of BCG’s effect. In several populations,
the efficacy of BCG is estimated to be greater than 75%. However,
in regions where TB remains endemic, no significant protection
from pulmonary TB in adults can be detected (19, 20). This vari-
able efficacy could be due to differences in the vaccine strain or
preparation, the environment, or the genetic background of the
host. The roles of genetic variation in the vaccine strain (21–24)
and previous exposure to environmental mycobacteria (25–27)
have been investigated extensively. In contrast, the role of host
genetic variation in BCG efficacy has been more difficult to quan-
tify. It is clear that variations in many immune mediators are
highly heritable (28–30). Many of these heritable variations af-
fect mediators that are likely to be relevant to M. tuberculosis im-
munity, such as the number of central memory T cells or the
abundance of cytokines like interleukin 12p40 (IL-12p40),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
alpha interferon (IFN-), and IL-6 (31). Indeed, numerous stud-
ies suggest that the immunological response to mycobacterial in-
fection (32–35) or BCGvaccination (36, 37) is heritable.However,
the relationship between these immunological markers and vac-
cine efficacy is unknown and very difficult to address in natural
populations. Thus, while there is reason to suspect that BCG effi-
cacy is influenced by genetic variation, it has proven difficult to
dissociate these effects from other confounding variables. In par-
ticular, the effect of BCG is difficult to dissociate from the intrinsic
TB susceptibility of each individual in a natural population.
In theory, animal models could be used to dissect the role of
genetic diversity in vaccine protection. However, while the mouse
model of TB has been very useful for understanding the mecha-
nisms underlying Mendelian susceptibility to TB, this approach
has proven less useful for understanding the complex trait genetics
that that have been shown to underlie TB susceptibility in mice,
with only 2 host loci so far identified from forward-genetic ap-
proaches (38–40). A fundamental limitation of the classic inbred
strains of Mus musculus domesticus that are generally used to
model TB is their genetic homogeneity, as 90 to 95% of these
animals’ genomes are estimated to be functionally identical (41).
As a result, these mouse strains mount qualitatively comparable
immune responses to this infection and vary only modestly in
their susceptibility toM. tuberculosis (42). In virtually every strain,
M. tuberculosis grows logarithmically for 2 to 3 weeks, at which
point bacterial growth is restricted by a strongTh1-biasedCD4T
cell response. Immunity depends largely on CD4 T cell-derived
IFN- and allows the animal to survive for several months har-
boring a relatively constant burden of bacteria. BCG vaccination
also produces a relatively homogenous effect in a variety of stan-
dard laboratory strains ofmice (43–45), accelerating the initiation
of adaptive immunity by several days, reducing the peak burden of
bacteria by approximately 10-fold (46), and extending survival
(47). It is often noted that the mouse model does not reproduce
many of the aspects of TB disease seen in humans or nonhuman
primates, including variable histopathology (48), progressive bac-
terial killing (49), and widely varying susceptibility (e.g., see ref-
erence 50). While these discrepancies are generally attributed to
species difference, the lack of variation observed inmice could also
reflect the low genetic diversity between classical inbred strains
(51). Thus, the true range of TB-related traits that can bemodeled
in mice remains unclear.
Tractable model systems that incorporate relevant genetic di-
versity could be used to decipher the genetic determinants of both
TB susceptibility and vaccine protection. Recently, a number of
related outbred model mouse populations have been developed
based on the same set of eight genetically diverse founder lines,
which represent all three M. musculus subspecies. The outbred
progeny of these strains, called the Diversity Outbred (DO) pop-
ulation, represent genetic diversity similar to that of a human
outbred population (52, 53) and display a remarkable heteroge-
neity in M. tuberculosis susceptibility (54). However, the com-
pletely outbred structure of this population imposes several limi-
tations on the resource. Most notably, each genotype is
represented by only a single animal. As a result, it is difficult to
quantify the genotype-specific effect of an intervention, such as
vaccination. To complement this resource, a panel of recombi-
nant inbred lines derived from the same founders was generated
and is called the “Collaborative Cross” (CC) (55, 56). The CC
panel retains the genetic diversity of DO animals but allows each
genotype to be infinitely reproduced. We took advantage of the
unique structure of the CC population to investigate the relation-
ship between host genotype, TB susceptibility, and BCG efficacy.
We found that the panel of parental and recombinant CC strains
(hereinafter named the “diversity panel”) reproduced many as-
pects of outbred populations and encompassed reproducible phe-
notypes that extend well beyond those observed in standard in-
bred strains. Using the diversity panel, we found that the efficacy
of BCG is genetically dissociable from susceptibility to TB and
correlates with intrinsic immune biases in the strains. This new
genetic resource identified an important role for host genetic di-
versity in vaccine efficacy and provides new approaches to under-
stand the immunological basis of protection and to optimize vac-
cines for outbred populations.
RESULTS
Genetically diverse mice display a broad range of phenotypes
upon M. tuberculosis infection. In order to independently assess
the contribution of host genotype toM. tuberculosis susceptibility
and vaccine protection, we assembled a population of highly di-
verse and reproducible inbred lines. This diversity panel con-
tained the eight founder lines of the CC and DO populations,
which include five relatively diverse classical inbred strains (A/J,
C57BL/6J, 129S1/SvImJ, NOD/LtJ, and NZO/H1LtJ) and three
wild-derived inbred strains (CAST/EiJ, PWK/PhJ, and WSB/EiJ),
hereinafter abbreviated to A/J, B6, 129, NOD, NZO, CAST, PWK,
and WSB. We also took advantage of additional recombinant CC
lines, since the range observed for polygenic traits in this type of
panel is often much greater in the genetically mosaic offspring
than in the founders (57, 58). Recombinant lines were included in
this panel based on their relative resistance or susceptibility to
Smith et al.
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M. tuberculosis after intravenous challenge, whichwas determined
in a related study.
To characterize the range ofM. tuberculosis susceptibility rep-
resented in the diversity panel, we infected groups of each geno-
type with strain H37Rv via the aerosol route and monitored dis-
ease over time.When the populationwas analyzed in the aggregate
(Fig. 1A, B, and C), we observed a range of susceptibility similar to
that observed in completely outbredDO animals derived from the
same founders (54). The lung and spleenCFUburdens varied over
a range of 1,000- to 10,000-fold, and some animals required eu-
thanasia after only 4 weeks of infection. When the panel was as-
sessed at the genotype level (Fig. 1D, E, and F), we found that these
differences in susceptibility were reproducible within each geno-
type and were therefore highly heritable. Based on the bacterial
burdens in lungs at 6 weeks postinfection, the genotypes could be
ranked based on susceptibility (Fig. 1D). The B6 strain, generally
considered to be the most resistant of the classical inbred lines
(59), showed intermediate susceptibility in our panel, maintain-
ing lung pathogen burdens of approximately 106 CFU throughout
the infection. The CC recombinant line, CC001, proved to be the
most resistant to infection by 6 weeks, while the wild-derived line
of M. musculus domesticus, WSB, was the most susceptible. The
phenotypes of these outlier strains were notable. CC001 was the
only line in the panel in which the lung CFU burdens decreased
between weeks 3 and 6 postinfection (P  0.044 by t test). This
relatively modest decrease was the first indication that this strain
progressively killsM. tuberculosis over time (as shown in the sub-
sequent studies presented below; see Fig. S2 in the supplemental
material). In contrast, the WSB and CC042 strains were both un-
able to control bacterial replication (P  0.0001 for WSB and
P  0.0001 for CC042 compared to B6 via one-way analysis of
variance [ANOVA] with Tukey’s multiple comparison test), lost
weight, (P 0.0039 forWSB andP 0.0004 forCC042 compared
to B6 via one-way ANOVA with Tukey’s multiple comparison
test), and were moribund after only 4 weeks of infection. Thus,
these genotypes were as susceptible as knockout mice lacking crit-
ical aspects of CD4 T cell-driven immunity, such as inducible
nitric oxide synthase (NOS2) (60) or major histocompatibility
complex class II (MHC-II) (61).
The ability to accurately measure multiple metrics of disease
over time in reproducible lines allowed the identification of traits
that are genetically separable. For example, the rate at which bac-
teria disseminate from the lung to the spleen varied across the
panel. Despite harboring similar numbers of M. tuberculosis bac-
teria in the lungs at 3 weeks postinfection, NOD mice and the
wild-derived strain ofM. musculus musculus, PWK, harbored sig-
nificantly fewer CFU in their spleens than B6 (P 0.020 for NOD
versus B6 and P 0.028 for PWK versus B6 by one-way ANOVA
with Tukey’s multiple comparison test). In the spleens of PWK
mice, theM. tuberculosis burden increased between 3 and 6 weeks
postinfection, indicating thatM. tuberculosis is able to replicate at
this site. Thus, the early deficit in spleen CFU in this genotype
could reflect delayed dissemination from the lung, which occurs
during this period and has previously been shown to vary with
host genotype (62). We conclude that the diversity panel encom-
passes a wide variation in TB susceptibility traits and that different
aspects of disease may be controlled by distinct genetic polymor-
phisms.
TB pathogenesis and immune response differ qualitatively
between strains.The polygenic basis of susceptibility in the diver-
sity panel suggested that distinct inflammatory and/or immuno-
logical pathways might underlie disease outcomes. Indeed, the
lungs of infected mice displayed lesional heterogeneity between
strains over time. At 3 and 6 weeks ofM. tuberculosis infection, the
lungs of B6 mice (the standard for mouseM. tuberculosis studies)
contained typical lesions for this strain, i.e., multifocal coalescing
histiocytic alveolar pneumonia with perivascular and peribron-
chiolar lymphocytic aggregates, no necrosis, and diminishing
neutrophils over time (Fig. 2A to C). The lungs of several similarly
resistant inbred strains (PWK and CAST) shared these character-
istics. In contrast, after only 3 weeks of infection, the susceptible
WSB strain had already developed dense neutrophilic inflamma-
tory infiltrates in small and large airways, which after one addi-
tional week of infection progressed to widespread necrosis of in-
flammatory cells and lung tissue, associated with morbidity.
Interestingly, theM. tuberculosis burden alone did not predict the
extent of lung damage or the type of microscopic lesions in all
cases. For example, the lungs of CC001 mice displayed early neu-
trophil recruitment and necrosis that was not apparent in other
similarly resistant lines and was resolved by 6 weeks postinfection,
when the bacterial burden had decreased in this strain. Thus, the
CC001 strain has some capacity to tolerate and resolve early ne-
crosis and neutrophilic-mediated lung damage due toM. tubercu-
losis infection.
Qualitative differences in the immune response were more ap-
parent when cytokine levels were measured in the lungs (Fig. 2D
and E). Immunity toM. tuberculosis in B6mice depends on IFN-
and tumor necrosis factor (TNF), which contribute to the effector
function of CD4 T cells (63, 64). Lung TNF levels were relatively
consistent across the panel at 3 weeks postinfection and were only
elevated in themoribundWSBmice after 4 weeks. In contrast, the
IFN- levels inmice with these genotypes varied by nearly 20-fold
at the early time point. Thewild-derived lines PWKandCAST and
the recombinant CC042 line expressed remarkably low levels of
this cytokine that were at or below the limit of detection (LOD) of
the assay (LOD  17 pg/ml). Splenocytes from PWK and CAST
mice both produced IFN- upon polyclonal stimulation ex vivo
(see Fig. S1 in the supplemental material), indicating that these
cells were capable of producing detectable levels of cytokine in our
assay. Thus, the lack of IFN- expression in the lungs of PWK,
CAST, and CC042 mice was not due to an inherent inability to
express the cytokine. Instead, these lines appear to mount a dis-
tinct response toM. tuberculosis infection, and the relative levels of
resistance of the CAST and PWK lines indicate that these re-
sponses can be effective in the absence of high levels of IFN-.
HostgenotypedeterminesBCGefficacy.Todeterminewhether
genetic polymorphism could influence the degree of protection
conferred by vaccination, we immunized a panel of diverse
mouse strains with BCG by the subcutaneous route. The mice
used for the vaccination study consisted of the same CC
founder strains, the highly resistant CC001 recombinant line,
and two additional recombinant lines representing susceptible
(CC019) and resistant (CC002) phenotypes. Twelve weeks af-
ter vaccination, viable BCG was not detected in spleen homog-
enates of all genotypes (LOD  20 CFU/spleen), indicating
that all mice were able to control infection with this attenuated
strain. The mice were then challenged withM. tuberculosis, and
the protection elicited by vaccination was determined at 4 and
14 weeks postinfection.
We initially analyzed this large panel as an aggregate popula-
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tion with 53 to 66 animals per group. As seen previously, the
bacterial burdens in the lungs and spleens of these animals varied
widely, and vaccination did not alter this variation (Fig. 3A andB).
BCG vaccination reduced themeanM. tuberculosis burdens in the
lungs or spleens by 1.7- to 4-fold at each time point, but even with
this large group size, the BCG-mediated reduction of bacterial
burden was only statistically significant at 4 weeks postinfection.
Thus, no durable protection fromM. tuberculosis growth could be
FIG 1 M. tuberculosis disease phenotypes in diversemice. (A to C) Lung CFU (A), spleen CFU (B), andweight change relative to initial weight (C) for individual
mice, colored by genotype, at weeks 3 and 6 (for CC001,NOD, 129, A/J, B6, PWK,CAST, andNZO lines) or weeks 3 and 4 (forWSB andCC042 lines, whichwere
moribund by week 4). (D to F) Average lung CFU (D), average spleen CFU (E), and average weight change (F) broken out by mouse genotype. (D to F) All data
are the average value SD for 3 or 4mice per strain at each time point. A statistically significant comparisonwithinmouse strains (P 0.05) using Student’s t test
is indicated by a triangle (o), and hash symbols (#) indicate statistical significance compared to the result for B6mice via one-wayANOVAwith Tukey’smultiple
comparison test (#, P 0.05; ##, P 0.01; ###, P 0.001)
Smith et al.
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detected in the aggregated data, which mirrors the lack of protec-
tion conferred by BCG in many natural outbred populations.
When the data were analyzed at the genotype level, it became
clear that the variation in CFU burdens was driven by genotype-
specific effects on both M. tuberculosis susceptibility and vaccine
efficacy (Fig. 3C and D). Using the reduction in M. tuberculosis
burden as a metric of vaccine efficacy, we defined “protection” as
a decrease in CFU of greater than 0.5 log10 that reached statistical
significance. Based on these criteria, only a subset of genotypes
was protected by vaccination. Consistent with previous litera-
ture, BCG reduced the bacterial loads in the lungs and spleens
of B6 mice by approximately 10-fold. This response was shared
in three other lines, two recombinants (CC001 and CC002) and
the wild-derived WSB line. In these genotypes, BCG exposure
reduced the M. tuberculosis loads by 10- to 100-fold. Notably,
these were the only genotypes in which vaccination protected
FIG 2 Distinct cytokine environments and histopathology results in diverse mice. (A) Representative images from B6, PWK, CAST, and WSB mice at2 and
20 magnification. (B) Proportional areas of granuloma occupied by necrosis, neutrophils, lymphocytes, and macrophages at 3 weeks postinfection (left) and
4 weeks or 6 weeks postinfection (right). Bar heights represent the average values from 10 randomly selected granulomas for each of 3 to 4mice permouse strain.
(C) Percentage of lung area that was damaged, measured using ImageJ to trace lesion size relative to the whole lung section. Bar heights represent the average
values from 3 or 4mice per strain. Error bars show standard deviations. (D and E) IFN- (D) and TNF (E) cytokines measured in homogenates of infected lungs
at 3 and 6 weeks (or 3 and 4 weeks forWSB and CC042 mice) postinfection. All data are the average value and SD from 3 or 4 mice per strain at each time point,
assayed in technical duplicate. Limit of detection (LOD) was calculated as twofold the background (17 pg/ml).
Discordant Control of TB Disease and Vaccine Protection
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the lung. BCG conferred protection in the spleens but not the
lungs of four additional lines (129, CC019, CAST, and A/J).
The remaining genotypes were not protected by vaccination in
either organ at any time point. In these nonresponding lines,
BCG vaccination either had no effect on the M. tuberculosis
burden or was associated with an increase in mean CFU, which
reached statistical significance for the NZO genotype (P 0.05
by t test). In most cases, an increased bacterial burden corre-
lated with weight loss (Fig. 3D). In mice of the WSB, CC002,
and B6 genotypes, BCG vaccination reduced the bacterial bur-
dens and significantly reversed weight loss at one of the two
time points. The effects of BCG on CFU and weight loss were
discordant for mice of the NZO and CC001 genotypes, reflect-
ing unique phenotypes that will be discussed below.
FIG 3 The effect of genetic background on BCG protection in diverse mice. (A and B) Lung CFU (A) and spleen CFU (B) in naive and vaccinated mice for all
genotypes. Each point represents the CFU for an individual mouse at the indicated time point. (C) Fold protection of eachmouse strain was calculated from the
average CFU of naive compared to BCG-vaccinated groups at 4 and 14 weeks postinfection in the lung and spleen. Coloring indicates CFU reduction (green) or
exacerbation (red) in the BCG-vaccinated group. “Protection” is defined as a statistically significant 0.5 log10 reduction in the BGC-vaccinated group. (D)
Average percent weight change of each mouse strain relative to initial body weight for BCG-vaccinated and naive mice at 4 and 14 weeks. The percent weight
changes were compared between naive and BCG-vaccinated mice within each mouse strain (unpaired t test). n 6 mice per strain per time point for naive or
BCG-vaccinated mice. *, P 0.05; **, P 0.01; ***, P 0.001.
Smith et al.
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TB susceptibility and BCG efficacy are genetically separable
traits. The ability to serially evaluate the same host genotype al-
lowed multiple traits to be measured independently in the vacci-
nated and unvaccinated state. To investigate potential mecha-
nisms that determine vaccine efficacy, we searched for correlates
of BCG-mediated protection among the traits measured during
primary infection. These traits included lung cytokine measure-
ments as a metric of adaptive immunity, CFU as a measure of
antimicrobial capacity, and weight loss as a surrogate for systemic
disease.
Upon correlating disease and immune metrics with the de-
gree of BCG protection, we identified a number of clusters of
covariant traits. A single cluster contained virtually all traits
associated with BCG-mediated protection, including all met-
rics of antimicrobial efficacy and protection from weight loss at
4 weeks postinfection (Fig. 4A, green box). The cluster did not
contain any traits related toM. tuberculosis susceptibility in the
unvaccinated state, and no specific correlation between M. tu-
berculosis susceptibility and BCG efficacy was evident (Fig. 4B
and C). Furthermore, BCG caused the largest reductions in
CFU in the CC001 and WSB lines, the most resistant and sus-
ceptible lines in the study, respectively (Fig. 4B, orange and
purple). Thus, M. tuberculosis susceptibility and BCG efficacy
were genetically separable.
In addition to all traits related to BCG protection, the BCG
efficacy-related cluster of traits also included another metric of
immune response that correlated strongly with the degree of
BCG-mediated protection, the early production of IFN- by un-
vaccinated animals (Fig. 3D and E). The capacity to produce other
T cell cytokines, such as TNF, was less predictive of BCG efficacy.
Upon examination of individual genotypes, two of the wild-
derived lines, CAST and PWK, were particularly notable for pro-
ducing nearly undetectable levels of IFN- upon M. tuberculosis
infection and receiving little or no benefit from BCG vaccination
(Fig. 4D and E, red and green).
Long-termprotection depends on a combination of traits. In
this panel of genetically diverse mice, we found that the extent of
disease at later time points depended on the intrinsic susceptibility
of the animal as much as the effect of vaccination. For example,
despite the nearly 100-fold reduction in lungM. tuberculosis bur-
den at 4 weeks postinfection, BCG only marginally extended the
survival of the highly susceptible WSB strain, from 4 to 6 weeks,
and ultimately did not protect this strain from disease. Con-
versely, even without vaccination, the resistant CC001 and CC002
strains had the remarkable ability to kill 90 to 95% ofM. tubercu-
losis bacteria between 4 and 14weeks postinfection (Fig. 3; see also
Fig S2 in the supplemental material). As a result, unvaccinated
animals of these genotypes harbored bacterial burdens at the later
time point that were similar to the burdens in the vaccinated B6
group. The relative resistance of this CC001 line likely explains its
ability to gain weight throughout the infection, regardless of BCG
vaccination (Fig. 3D).
We also found that mice could benefit from vaccination
even if the M. tuberculosis burden was not reduced. For exam-
ple, even though BCG-vaccinated NZO mice harbored signifi-
cantly more M. tuberculosis bacteria in their lungs than their
unvaccinated counterparts at 4 weeks postinfection, vaccina-
tion still reversed M. tuberculosis-induced weight loss between
4 and 14 weeks (Fig. 3D). The NZO mouse strain has been
described to develop a polygenic form of type II diabetes at
about the same age as the animals used in our study (65). As
chronic hyperglycemia can increaseM. tuberculosis susceptibil-
ity in mice (66, 67), we hypothesized that an interaction be-
tween vaccination and diabetes initiation might underlie the
paradoxical effects of BCG on M. tuberculosis burden and
weight loss. Indeed, while 5 of 6 unvaccinated animals were
found to have fasting blood glucose levels above 500 mg/dl at
14 weeks postinfection, 0 of 6 vaccinated animals were diabetic
(Fig. 5A and B). In the NZO genotype, diabetes strongly pre-
dicted weight loss but not CFU (Fig. 5C and D). Our diversity
mouse panel also included NOD mice that develop autoim-
mune type I diabetes (68). No significant effect of BCG on
either M. tuberculosis burden or blood glucose concentration
was evident in this strain, possibly due to the variable pen-
etrance of diabetes (see Fig. S2J in the supplemental material).
Thus, the major protective effect of BCG in M. tuberculosis-
infected NZO mice appears to be the prevention of type II
diabetes. Taken together, our observations in the genetic diver-
sity panel suggest that while the protective efficacy of BCG can
be separated from TB susceptibility, the ultimate effect of vac-
cination on the outcome of infection is influenced by a variety
of factors, including intrinsic susceptibility to TB and complex
interactions with comorbidities, such as diabetes.
DISCUSSION
Predicting TB risk and rationally designing more effective inter-
ventions will ultimately require understanding the mechanisms
that control the outcome of M. tuberculosis infection in a geneti-
cally diverse population. An ideal experimental model to dissect
these mechanisms would encompass relevant genetic diversity
and allow the serial evaluation of genetically identical individuals.
To create such a population, we took advantage of the Collabora-
tive Cross project, which identified genetically diverse founder
lines of mice and generated recombinant inbred animals in which
this diversity was reassorted to produce more extreme pheno-
types. Our studies using this panel extended the phenotypic diver-
sity described in the species and allowed the contributions of host
genetics to TB susceptibility and BCG efficacy to be assessed inde-
pendently.
The course of M. tuberculosis infection in the standard
“mouse model” (B6 inbred strain) is often contrasted with the
diversity of TB-related disease that is apparent in other species.
For example, while M. tuberculosis can replicate continually at
some sites in the lungs of cynomolgus macaques, M. tubercu-
losis is efficiently killed in most of the granulomas (49). These
studies are consistent with observations from human autop-
sies, which similarly suggest that M. tuberculosis is eradicated
frommany granuloma and only replicates in a minority of sites
(69). In contrast, with the exception of a few susceptible sub-
strains (54, 70), M. tuberculosis infection of standard labora-
tory strains of M. musculus domesticus follows a very similar
course; M. tuberculosis replication can generally be controlled,
but the mice are unable to clear the pathogen or even to signif-
icantly reduce the lung bacterial burden during the persistent
phase of infection when the M. tuberculosis burden remains
stable. Our studies suggest that this homogeneity in TB patho-
genesis reflects the genetic homogeneity of these strains, but
not the phenotypic diversity of the species. Of course, the
mouse lines used in this study may not capture all diversity
previously described in mouse substrains. For example, the
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FIG 4 Phenotypic relationships between M. tuberculosis susceptibility and BCG efficacy. (A) Hierarchical clustering of correlations between metrics of
susceptibility at weeks 3, 4, 6, and 14 postinfection and response to vaccination at weeks 4 and 14 postinfection. Blue indicates positive Pearson’s correlations, and
red indicates negative correlations. “Protection” indicates the relative reduction in CFU or weight loss in the BCG-vaccinated group. “Weight” indicates percent
weight change relative to initial body weight. “L” and “S” indicate lung and spleen, respectively; “N” and “BCG” indicate naive and vaccinated groups. Green box
indicates the trait cluster containing metrics of BCG-mediated protection. (B and C) Lack of correlation between TB susceptibility and BCG efficacy at early (B)
or late (C) time points. (D and E) Positive correlation between IFN- production afterM. tuberculosis infection and BCG efficacy in the lung (D) or spleen (E).
Solid lines are correlations of results at the 4-week time point (circles), and dotted lines are correlations of results at the 14-week time point (squares); each data
point in panels B to E is the average value from 3 to 6mice per genotype. Note that NODmice are not displayed on the correlation plots due to the highly variable
response of this strain (see Fig. S2J in the supplemental material).
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C3HeB/FeJ substrain forms caseating lung lesions upon M. tu-
berculosis infection (70), which closely resemble those of hu-
mans. Determining whether any mouse lines in the CC panel
recapitulate this phenotype will require additional infections
studies in parallel with C3HeB/FeJ animals.
Phenotypes ranging from progressive killing of M. tubercu-
losis to extreme susceptibility were present in our panel and
appear to be based on different underlying genetic mecha-
nisms. The ability to kill M. tuberculosis during the persistent
phase of infection (between 4 and 14 weeks) was found only in
recombinant animals and not the founder lines, suggesting that
this is a multigenic trait that depends on the proper assortment
of founder alleles. In contrast, several extreme phenotypes were
evident in the more divergent wild-derived lines. The WSB line
of M. musculus domesticus was extremely susceptible to M. tu-
berculosis. This line has also been recently reported to be mod-
estly susceptible to influenza A virus infection (71). However,
these animals are otherwise healthy and able to control the
replication and dissemination of BCG, suggesting a fairly spe-
cific defect in immunity toM. tuberculosis. While the CAST line
of M. musculus castaneus and the PWK line of M. musculus
musculus appeared similarly as susceptible to TB as many stan-
dard lines, their response to infection differed from those of
other genotypes in several respects. The lungs of CAST mice
displayed a paucity of inflammatory infiltrate relative to the
levels in other mice that harbored similar bacterial burdens, a
trait also reported for this genotype during influenza virus in-
fection (71). PWK animals were able to delay the dissemination
of M. tuberculosis from the lung to the spleen. Most strikingly,
both CAST and PWKmice produced barely detectable levels of
IFN- during infection. While this cytokine is critical for M.
tuberculosis immunity in B6mice, these strains were still able to
control bacterial replication. CD4 T cells have been shown to
control M. tuberculosis growth through IFN--independent
mechanisms in several settings (72, 73), and Th17 cells have
been specifically implicated in protection (74). Together, these
observations suggest that these highly divergent mouse lines
might preferentially depend on non-Th1-biased CD4 T cell
responses for M. tuberculosis immunity.
The structure of our mouse population allowed us to deter-
mine that BCG efficacy is controlled independently of TB suscep-
tibility in naive animals. These observations suggest that even the
most susceptible individuals can benefit from vaccination. How-
ever, the genetic basis of vaccine-conferred protection remains
unclear. The animals in our panel encode diverse MHC haplo-
types, raising the possibility that H2 polymorphism could influ-
ence the degree of protection (40). However, MHC haplotype
alone is unlikely to explain the dramatic differences that we ob-
served, since BCG produces a large and diverse array of potential
antigens. In addition, two strains in our panel (129 and B6) shared
the same H2 haplotype and were differentially protected, further
indicating that additional mechanisms determine BCG efficacy.
Similarly, while the relative ability to eradicate BCG could control
efficacy, previous studies found that this vaccine protects animals
FIG 5 BCG protectsM. tuberculosis-infected NZOmice from diabetes. (A) Blood glucose measurements obtained from naive and BCG-vaccinated NZOmice
at 4 and 14 weeks postinfection. Mice were fasted for 6 h prior to obtaining blood glucose measurements. Mice were considered diabetic if they had a blood
glucose concentration greater than 200 mg/dl. (B) Percent weight changes of naive and BCG-vaccinated mice relative to initial mouse weights at 4 and 14 weeks
postinfection. Correlation of blood glucose versus lungCFU (C) and correlation of blood glucose versusweight change (D) at 14weeks postinfection in naive and
BCG-vaccinatedmice. Each data point is the value for an individual NZOmouse at each specified time point. Naive and BCG-vaccinated groups were compared
by Student’s t test. *, P 0.05; **, P 0.01; ***, P 0.001.
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of widely varying BCG susceptibilities, which were determined by
Nramp1 (Slc11a1) polymorphism (44). Instead, the observed cor-
relation between the propensity of an unvaccinated strain to
produce IFN- after M. tuberculosis infection and the degree of
BCG-induced protection suggests that intrinsic bias in the anti-
mycobacterial immune response could influence vaccine efficacy.
While this correlation was driven by both classical and wild-
derived lines, the CAST and PWK lines were particularly strong
outliers. These strains made very low levels of IFN- after infec-
tion and received virtually no benefit from BCG. Thus, it is possi-
ble that while BCG is a robust inducer of canonical antimycobac-
terial Th1 responses, it is unable to stimulate the immune
response(s) that protect these highly divergent strains.
The low and variable degree of protection elicited by BCG in
natural populations could be due to either a general lack of efficacy
or a differential effect in distinct individuals. It is important to
understand the relative importance of these two factors, since en-
tirely different approaches are necessary to overcome them. Our
observations using amodel population of genetically diverse mice
indicate that genetic diversity in the host population could be a
major factor limiting BCG efficacy. Based on these findings, it is
not clear that optimizing a vaccine to protect a single standard
laboratory strain of mouse will produce an intervention that is
broadly efficacious in an outbred population or even that a single
vaccine is capable of protecting genetically diverse individuals.
Instead, optimizing a vaccine or set of vaccines to protect nonre-
sponding strains may represent amore effective strategy. Further-
more, understanding the immunological biases that determineTB
susceptibility and vaccine efficacy would facilitate the identifica-
tion of individuals that are genuinely at risk. The large panel of
recombinant inbred Collaborative Cross lines that is currently
available will allow the genetic dissection of these traits and should
facilitate the development of more broadly effective vaccination
strategies.
MATERIALS AND METHODS
Ethics statement. The animal studies were approved by the Institutional
Animal Care andUseCommittee at theUniversity ofMassachusettsMed-
ical School (UMMS; Animal Welfare Assurance no. A3306-01), using the
recommendations from the Guide for the Care and Use of Laboratory An-
imals of the National Institutes of Health and the Office of Laboratory
Animal Welfare (75).
Mice. C57BL/6J (stock number 0664), A/J (stock number 0646),
129SvImJ (stock number 02448), NZO/HiLtJ (stock number 02105),
NOD/ShiLtJ (stock number 01976), WSB/EiJ (stock number 01145),
PWK/PhJ (stock number 3715), and CAST/EiJ (stock number 0928)mice
were purchased from the JacksonLaboratory (BarHarbor,ME,USA), and
Collaborative Cross strains CC001, CC002, CC019, and CC042 were pur-
chased from the University of North Carolina (Chapel Hill, NC, USA).
Malemice were 8 to 12 weeks old at the start of all experiments.Mice were
housed under specific-pathogen-free conditions and in accordance with
the University ofMassachusetts (UMASS)Medical School IACUC guide-
lines.
Vaccination. Mice were vaccinated with 105 CFU BCG (BCG SSI
strain, resuspended in 0.04% phosphate-buffered saline [PBS]–Tween
80) via the subcutaneous route (100 l per mouse). Mice were rested for
12 weeks; 3 mice per genotype were euthanized at 12 weeks postvaccina-
tion and their spleens homogenized and plated to test for BCG persis-
tence. Twenty-four mice per genotype were subsequently infected with
M. tuberculosis, of which 12 were vaccinated and 12 were naive.
Experimental infection and bacterial quantification. Infection with
M. tuberculosis (H37Rv strain; phthiocerol dimycoserosate [PDIM] posi-
tive) was performed via the aerosol route, with mice receiving 50 to
200 CFU. Bacteria were cultured in 7H9 medium containing 0.05%
Tween 80 and oleic acid-albumin-dextrose-catalase (OADC) enrichment
(Becton, Dickinson). For infections, mycobacteria were suspended in
PBS-Tween 80 (0.05%); clumps were dissociated by sonication, and inoc-
ulum delivered via the respiratory route using an aerosol generation de-
vice (Glas-Col). To determineCFU,micewere anesthetized via inhalation
with isoflurane (Piramal) and euthanized via cervical dislocation, the or-
gans aseptically removed and individually homogenized, and viable bac-
teria enumerated by plating 10-fold serial dilutions of organ homogenates
onto 7H10 agar plates. Plates were incubated at 37°C, andM. tuberculosis
colonies counted after 21 days.
Cytokine measurement in tissue homogenates. Murine cytokine
concentrations weremeasured from culture supernatants (prepared from
uninfected splenocytes from 3 mice per genotype that were diluted to 1
million cells per well and stimulated by phorbol 12-myristate 13-acetate/
ionomycin [PMA/I] or anti-CD3/CD28 antibody for 72 h) or cell-free
lung homogenates and quantified using commercial ELISA kits for IFN-
and TNF (DuoSet, catalog numbers DY485, DY410, and DY402; R & D
Systems). The final values are the average values from 3 mice per geno-
type, with each individual mouse sample run in technical duplicate.
Light microscopy. Lung lobes from 3 or 4 individual mice per time
point were fixed with 10% neutral buffered formalin, processed, embed-
ded in paraffin, sectioned at 5 m, and stained with hematoxylin and
eosin. Two serial sections were examined by a board-certified veterinary
pathologist (G.B.) for qualitative analyses, including assessment of im-
mune/inflammatory cell types, distribution and extent of lesions, pres-
ence and absence of necrosis, and extent and content of disrupted lung
architecture. The extent of necrosis and neutrophil, macrophage, and
lymphocyte influx was then estimated per strain per time point by blindly
assessing 10 granulomas chosen at random, and the results reported as the
proportional areas occupied by necrosis, neutrophils, lymphocytes, and
macrophages.
Statistical analysis. All data are represented as mean values and stan-
dard deviations (SD). The statistical significance of differences between
data groupswas determined using the unpaired two-tailed Student’s t test,
and that of differences in genotypes compared to the standard B6 strain by
one-way ANOVA with Tukey’s multiple comparison test, using Graph-
Pad Prism 7. Pearson’s correlation was used to determine correlations
between measured traits, and the results visualized using corrplot version
0.77 (ordered by hclust) in R version 3.2.4.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01516-16/-/DCSupplemental.
Figure S1, TIF file, 10.4 MB.
Figure S2, PDF file, 1 MB.
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